C ardiovascular disease is the most common cause of mortality in the industrialized world and represents 31% of global deaths. 1 Atherosclerosis is regarded as a chronic inflammatory disease of the arterial wall, manifesting in cardiovascular events, such as myocardial infarction or stroke. Hypercholesterolemia, hypertension, and cigarette smoking are the most common risk factors of atherosclerosis and accelerate the inflammatory process.
Neutrophils and their effector molecules have been identified in murine and human atherosclerotic plaques by immunohistochemistry and fluorescence techniques, such as flow cytometry and confocal microscopy. 4, 6, 7, [9] [10] [11] Functionally, it has been demonstrated that neutrophils accumulate within atherosclerotic vessels, in particular, during early plaque formation and secret preformed granule proteins, which may instruct recruitment and activation of other inflammatory cells 12 to promote atherosclerotic lesion formation.
Extracellular proteolytic processes modulate plaque stability. Breakdown of extracellular matrix by matrix metalloproteinases and cathepsins can increase the vulnerability of the plaque, rendering it prone to rupture, a mechanism that can trigger sequelae, such as myocardial infarction or stroke. Neutrophil elastase in this process additionally contributes to matrix degradation and weakening of the vessel wall. 13 Preclinical imaging technologies enable novel insights into cardiovascular diseases because they can depict the dynamic expression of biomarkers during disease development. Fluorescence molecular imaging has emerged as a powerful tool because it can target multiple biological aspects of the disease by using high-affinity ligands labeled with near-infrared fluorochromes that are directed toward key cellular and molecular players of atherosclerosis.
14 Fluorescence molecular tomography (FMT) fused with x-ray computer tomography (XCT) cannot only detect but also quantify inflammatory processes in atherosclerotic lesions dynamically in vivo and over time. [14] [15] [16] To date, molecular imaging has primarily focused on the detection of monocytes/macrophages and their effector molecules, such as cathepsins and matrix metalloproteinases. Molecular imaging of neutrophils as early contributors to atherosclerotic lesion formation and elastase as its major effector is expected to be challenging. Neutrophils have a short life span and undergo rapid functional phenotypic changes. 17 In addition, the number of neutrophils and plaque size during early phases of atherosclerosis is limited. 4, 7, 12, 18 Capturing neutrophils or neutrophil elastase noninvasively and in vivo will, therefore, require a technology with adequate sensitivity. However, the possibility to track early stages of atherosclerotic lesion formation in vivo could offer novel insights into the pathophysiology and maturation process. Additionally, it enables the assessment of treatment regimens that aim at targeting atherosclerosis at an early stage, before plaque formation becomes irreversible and plaque rupture can occur.
The aim of our study was, therefore, to investigate neutrophil elastase-targeted FMT for the early assessment of atherosclerotic lesion formation in a murine model of atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Elastase-Targeted Near-Infrared Fluorescence Agent Is Activated by Isolated Neutrophils in a Concentration-Dependent Manner
We first tested activation of the elastase-specific near-infrared fluorescence (NIRF) agent by neutrophils. To this end, murine neutrophils were isolated from bone marrow and characterized by multicolor flow cytometry. Isolated neutrophils were identified as CD11b +
Ly6G
+ cells within CD45 + leukocytes and reached a purity of >90% ( Figure 1A) .
The NIRF agent can be activated by neutrophil elastase that is usually stored in neutrophil cytoplasmic granules. 19 We, therefore, first analyzed activation of different concentrations of the NIRF agent by lysed neutrophils and could evidence a concentration-dependent increase of emitted fluorescence over time, using both murine and human neutrophils, corresponding to K m values of 7.3 and 11.2 μmol/L, respectively ( Figure 1B and 1C). To further test the specificity of the imaging agent, competition experiments were performed using the selective elastase inhibitor sivelestat 20 with both mouse and human neutrophils. Dose-response curves after inhibition with different concentrations of sivelestat demonstrated effective inhibition of the activation of the NIRF agent ( Figure 1D and 1E), as also evident after calculating inhibition curves ( Figure 1F and 1G) , showing a half maximal inhibitory concentration of 0.9 and 48 nmol/L for murine and human neutrophils, respectively, confirming high specificity of the imaging agent.
In vivo, intracytoplasmatic granules are released from neutrophils on stimulation of the cells. We next assessed activation of the elastase-targeting NIRF agent by neutrophils stimulated with different concentrations of phorbol-12-myristate 13-acetate/ionomycin or N-formyl-Met-Leu-Phe (Figure 2A through  2D) . Indeed, the probe was rapidly activated by phorbol-12-myristate 13-acetate/ionomycin-stimulated murine neutrophils in a concentration-dependent manner (Figure 2A ), whereas N-formyl-Met-Leu-Phe-activation of murine neutrophils showed less potent activation of the fluorescent probe ( Figure 2C ). No activation of the probe was detected in unstimulated neutrophils (Figure 2A and 2C) . Human neutrophils activated with phorbol-12-myristate 13-acetate/ ionomycin generated a fluorescent intensity that was twice as high when compared with murine neutrophils. N-FormylMet-Leu-Phe challenging of human neutrophils only marginally increased the fluorescence intensity of the activated probe when compared with nonactivated neutrophils, which served as a control ( Figure 2D ). Of note, already nonactivated control human neutrophils showed a mild increase of emitted fluorescence when incubated with the NIRF agent over time, which may reflect low levels of spontaneous activation ( Figure 2B ).
Taken together, the evaluated elastase-targeted fluorescent agent is specifically activated by exposure to both murine and human neutrophil contents after lysis, as well as by activated neutrophils in a concentration-dependent manner. with the elastase-targeted NIRF agent, and hybrid contrastenhanced XCT enabled colocalization of the fluorescence signal predominantly to the aortic root and arch. Control mice without atherosclerosis showed only weak and unspecific fluorescence signal after injection with the probe ( Figure 3A ). The mean fluorescence intensity, calculated for the region of interest (root and aortic arch), peaked at 4 weeks of HFD and decreased slightly at 8 and 12 weeks of HFD ( Figure 3B ). To rule out a major contribution of autofluorescence to this signal, we additionally imaged mice after 4 weeks of HFD without injection of the NIRF contrast agent. However, the captured autofluorescence in these mice proved to be negligible ( Figure 3B ). Furthermore, mice injected with the NIRF agent before the initiation of HFD, without any atherosclerosis, showed only moderate background fluorescence, attributable to unspecific activation within the circulation ( Figure 3B ).
In Vivo FMT-XCT of Elastase
Fluorescence Elastase Signal in the Aortic Arch Is Confirmed by Whole-Body Cryoslicing
To confirm that the fluorescent signal emitted from the elastase-targeted NIRF agent originates from the aorta of atherosclerotic mice, whole-body cryoslicing was performed, which provides an increased spatial resolution of the emitted fluorescence compared with in vivo FMT. Representative cryoimages of the arch of control and atherosclerotic mice injected with the NIRF agent are shown, as well as images of mice not injected with the probe depicting background autofluorescence ( Figure 4A ). Fluorescent ratios of the aortic arch were calculated for each time point. Similar to results obtained in vivo, signal intensities in these areas increased after initiating the HFD and peaked at 4 weeks and decreased in the later course of atherosclerosis ( Figure 4B ). Autofluorescence intensities of mice at 4 weeks of HFD not injected with the NIRF agent were again low ( Figure 4B ).
Activated NIRF Agent Is Located in the Atherosclerotic Arterial Wall
To further investigate the exact location of the fluorescent signal of the elastase-targeting NIRF agent within the arterial wall, fluorescent microscopy was used. Increased signals in the near-infrared light spectrum (680 nm) were localized to the endothelial cell layer and plaque region in the aortic arch ( Figure 4C ). In addition, intense near-infrared signal of the elastase-targeting NIRF agent was detected within plaque regions in colocalization with Ly6G + neutrophils, as revealed by confocal microscopy and immunofluorescence staining in adjacent plaque sections of the aortic root ( Figure 4D ). However, it should be noted that the NIRF signal could also be detected in plaque regions devoid of any Ly6G staining, representing elastase deposits within the atherosclerotic plaque that may have originated from short-lived neutrophils or other cell types.
Histological Analysis of Plaque Size and Neutrophil Counts in Atherosclerotic Lesions
To quantify the progression of atherosclerosis, plaque area was measured in histological sections of the aortic root and aortic arch. Plaque size increased over time in both regions ( Figure 5A and 5B). To further localize neutrophils in atherosclerotic lesions, immunohistochemical staining of Ly6G was performed. Ly6G + neutrophils were located in both the atherosclerotic plaques in the aortic sinus, as well as in lesions of the aortic arch ( Figure 5C and 5D). The number of neutrophils per plaque area was increased at 4 and 8 weeks of HFD in the aortic root and was lower at 12 weeks of HFD. In the aortic arch, the number of neutrophils peaked at 4 weeks of HFD, followed by a decline in the further course of the study. Frequencies of neutrophils were higher in the aortic arch region compared with the aortic root ( Figure 5A and 5B).
Discussion
Inflammatory processes are driving forces of atherosclerotic plaque development. Monocyte recruitment and macrophage differentiation, as well as the uptake of modified low-density lipoproteins by macrophages, lead to signaling cascades that result in the expression and release of chemokines, proinflammatory cytokines, and proteases attracting other inflammatory cells to stimulate the inflammatory process. 23 In recent years, also neutrophils have been revealed to support early atherosclerotic plaque development. 5 Neutrophils can prime monocyte recruitment. 12 Moreover, neutrophil extracellular traps that are released by neutrophils that undergo a specific cell death and consist of decondensed chromatin containing neutrophil elastase and myeloperoxidase 24 can be found within arteries of atherosclerotic mice. 25 Investigating the interplay between macrophages and neutrophils, neutrophil extracellular traps were shown to prime macrophages for cytokine release, boosting the inflammatory process and promoting atherosclerotic lesion formation. 26 The possibility of tracking early events in atherosclerotic lesion formation in vivo would not only offer novel insight into the pathogenesis of atherosclerosis but also enable the assessment of pharmacological interventions targeting atherosclerosis at a stage that is at least partially reversible. To evaluate the potential of molecular imaging during early stages of atherosclerosis, we assessed the performance of an elastasetargeting near-infrared imaging agent to capture elastase activity noninvasively and in vivo.
It has previously been shown by Kossodo et al that the probe used in our study is preferentially cleared and rapidly activated by neutrophil elastase (both in mice and humans) and is resistant to other serine proteases. 27 We have confirmed that the elastase-targeted NIRF imaging agent showed a dosedependent activation by proteases secreted after isolation and stimulation of both murine and human neutrophils. The specificity of the probe was tested by conducting inhibition experiments with sivelestat. Sivelestat is a selective inhibitor of murine and human elastase and is clinically used in acute lung injury. 28 Sivelestat inhibited human neutrophil elastase with a half maximal inhibitory concentration value comparable to published data. 20 Mouse elastase inhibition with sivelestat was more powerful compared with inhibition of human elastase.
After successful evaluation of the NIRF probe ex vivo, we subsequently studied the probe performance in vivo in a murine model of atherosclerosis. FMT-XCT as a noninvasive imaging approach allows the detection of protease activity in vivo. The assessed probe was recently investigated in a mouse model of acute lung injury, 19 in a tumor mouse model with neutrophil elastase activity, 29 and in chlamydia-associated inflammation. 30 In our study, we measured the fluorescent signal in vivo by hybrid FMT-XCT, which enabled the anatomic localization of the targeted fluorescence to regions of the aortic root and arch of atherosclerotic mice. The measured fluorescence increased at 4 weeks of HFD and slightly declined again at 8 and 12 weeks of HFD. These NIRF signals generated by the neutrophil elastase 680 probe appear large and diffuse because of scattering in the biological tissue so that reconstruction of a high-resolution image with FMT-XCT is difficult, in line with previous reports. [31] [32] [33] [34] Ex vivo experiments of whole-body cryoslicing corroborated the in vivo results and confirmed increased fluorescence signals originating from the aortic wall, and quantification of cryoslicing results similarly showed an increased fluorescence signal at 4 and 8 weeks, thus, at early stages of lesion development.
Fluorescence ratios were calculated to evaluate the fluorescence signal in cryosections in between mice. Because of distinct integration times of the camera as a result of slight changes of the laser light direction relative to the region of interest, its distance to the camera, and so forth, there were differences in the dynamic range of fluorescence in each mouse, even after reducing background effects, so that the fluorescence ratio was calculated for quantitative comparison. Higher variability of the fluorescence ratio at 8 and 12 weeks may have been caused by difficulties of manual segmentation in the region of interest (close to the aorta) because of its small size and relative low signal intensity, whereas the same is not a problem with FMT-XCT data. FMT-XCT data offer a more accurate localization of the aorta because of better anatomic information of the XCT. Manual segmentation of the region of interest is also less difficult at 4 weeks of HFD because the signal intensity in these mice is higher, associated with a much higher fluorescence ratio, hence, enabling a more accurate segmentation with lesser variability. However, it has to be conceded that spatial resolution of FMT remains limited. Scattering of emitted fluorescence from deep tissue results in a diffuse FMT signal, which may seem to extend the region of interest in the aortic arch, similar to previous findings. [31] [32] [33] [34] In addition, the fluorescence signal observed in FMT-XCT imaging contains fluorescence emitted from the target, but also background autofluorescence, as well as fluorescence that may have been scattered from signals outside the blood vessel or adjacent mediastinal structures. Signals in the region of the aortic arch may, thus, not only originate from fluorescence emitted from plaque tissue but also from, for example, extravascular activation or trapping of the cleaved product. Those signals cannot be separated by FMT inversion. This may also be reflected by our FMT-XCT quantification results: at week 0, there is still a positive quantification value rather than zero, which may indicate the extent of autofluorescence and extravascular probe activation. However, signal intensities are much stronger in atherosclerotic mice at week 4, week 8, and week 12. This increase in fluorescence strongly indicates that despite the limitations in spatial resolution, elastase-targeted FMT-XCT imaging can be used for in vivo detection of early atherosclerosis.
Fluorescence microscopy additionally verified the presence of emitted fluorescence from the elastase targeting NIRF agent in the atherosclerotic aorta and regions of plaque formation. A major contribution of plaque autofluorescence was ruled out by investigating atherosclerotic mice not injected with the NIRF probe, which did not show any fluorescence. These results, thus, demonstrate that the measured elastase activity is primarily associated with early-stage atherosclerotic lesions.
Immunofluorescence staining and histological analyses were conducted to assess the number and localization of intralesional neutrophils. The number of neutrophils per plaque area was increased at 4 and 8 weeks after initiation of HFD and decreased thereafter, in accordance with previously described kinetics. 4, 18 The relative number of neutrophils corresponded to the results of elastase activity determined by FMT-XCT in vivo and by cryosection analysis ex vivo. Correlation analyses of cell numbers with fluorescence signals of all mice fed a HFD in vivo, however, did not reveal a significant correlation. It should be noted, however, that neutrophil counts within plaque tissue are low (≈5 neutrophils per square millimeter of plaque), so that it is unlikely that living neutrophils are solely responsible for the elastase fluorescence signal. Lin et al 15 conducted an FMT imaging study with atherosclerotic mice using cathepsin and α V β 3 integrin NIRF agents. The minimum macrophage cell count was around 100 for correlation to the FMT signal. However, neutrophils have a short life span, so that low numbers visualized by histology may not necessarily correspond to the total number of recruited neutrophils. In addition, neutrophils contain preformed granules containing different effector molecules, such as neutrophil elastase. These may be released and deposited within the artery 35, 36 and may persist even after neutrophil cell death. Similarly, elastase-containing neutrophil extracellular traps can be found within the arterial wall. 26 In line, in some cases, we could clearly colocalize the fluorescence signal of the elastase NIRF probe to specific cells with segmented nuclear morphology typical for neutrophils and Ly6G staining, whereas we were also able to detect staining of the NIRF probe in plaque regions without colocalization with Ly6G. This may have been caused by the presence of elastase deposits still present after the donor neutrophil has died. Another explanation why a measurable fluorescent elastase signal can be detected despite low numbers of neutrophils is that neutrophil elastase may also be derived from alternative sources. Dollery et al 13 showed that activated vascular endothelial cells, monocytes, and macrophages contain neutrophil elastase mRNA and can produce neutrophil elastase. Thus, endothelial cells themselves and early infiltrating mononuclear phagocytes may in addition contribute to lesional elastase activity. In addition, it could also be possible that other enzymes contribute to the fluorescent signal by unspecific cleavage of the amino acid sequence of the NIRF agent. Potential protease substrate cleavage sites can be predicted using a published online tool. 37 This indicated potential substrate cleavage also by matrix metalloproteinases 9 and cathepsin G for the amino acid sequence of the assessed probe, which needs to be investigated in future experiments.
The key advantage of molecular imaging is the ability to track inflammatory processes noninvasively. Nahrendorf et al 14 successfully tested different NIRF agents specific for proteases in atherosclerotic lesion. In addition, integrin-targeted FMT imaging offered new insights as a molecular imaging tool of atherosclerosis. 15 Besides FMT, also magnetic resonance imaging may constitute a preclinical imaging approach focusing on enzyme-sensitive magnetic resonance agents. Myeloperoxidase, secreted predominantly by neutrophils, plays a central role in plaque, destabilizing at later stages of atherosclerosis. The study conducted by Ronald et al 38 showed myeloperoxidase activity using a myeloperoxidase magnetic resonance sensor in atherosclerotic rabbits noninvasively. These studies, however, uniformly addressed later stages of atherosclerosis.
Early-stage atherosclerosis may still be reversible to a certain degree. Sivelestat, a synthetic neutrophil elastase inhibitor, effectively reduced inflammation in acute lung injury in animal models and clinical trials. 28, 39 However, sivelestat has not been investigated in the context of atherosclerosis. Taking recent work by Warnatsch et al 26 and our results into account, the presence of neutrophil elastase in early atherosclerotic lesions may suggest its suitability for pharmacological intervention. Likewise, pharmacological interventions suppressing the early progression of atherosclerosis could potentially be monitored in vivo by detecting elastase activity.
Although fluorescence molecular imaging has long been restricted to preclinical setups, its clinical translation is within reach. Miniaturization of fluorescence detectors has enabled mounting the entire instrumentation of angiography catheters, already evaluated successfully in large animal models of atherosclerosis. 40, 41 Detection of early atherosclerotic lesions in patients before calcifications occur is limited using current technologies of biomedical imaging. Detection of neutrophil elastase using catheter-based fluorescence imaging would enable to capture early lesion formation also in patients, thereby, enabling tailored treatment approaches. Similarly, because elastase plays an import role during plaque rupture, catheter-guided detection of vulnerable atherosclerotic lesions might become feasible in the clinical setting.
In summary, the present study provides new insights into elastase-targeted imaging of early stages of atherosclerosis. Our findings show that the assessed probe can be used as a fluorescent biomarker of elastase activity in atherosclerotic mouse models. This specific imaging approach could, thus, be explored for application in a clinical setting for earlier diagnosis and treatment of atherosclerosis.
